Tandem Diabetes price target raised to $60 from $58 at Barclays

Barclays raised the firm’s price target on Tandem Diabetes (TNDM) to $60 from $58 and keeps an Overweight rating on the shares. The company delivered another solid growth quarter, raising growth guidance for the full year to 17%-18%, driven largely by continued success of the Mobi launch, the analyst tells investors in a research note.